Drug intelligence / Profile preview

Medox C Forte

Development stage: Unknown
Lead developer: CAPS Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Medox C Forte is a topical antibiotic ointment developed and marketed by CAPS Holdings (CAPS Pharmaceuticals) in Zimbabwe. The product contains oxytetracycline, a broad-spectrum antibiotic belonging to the tetracycline class. It is specifically indicated for the treatment of infected wounds, cuts, and skin irritations such as nappy rash (diaper dermatitis) in infants. Oxytetracycline exerts its antimicrobial effect by binding to the 30S ribosomal subunit of susceptible bacteria, which inhibits the binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby halting protein synthesis and preventing bacterial growth and replication.

Brand names: Medox C Forte

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on Medox C Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medox C Forte.

Explore the full profile